Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
<h4>Purpose</h4>To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849766513372823552 |
|---|---|
| author | Amy P Abernethy Ashwini Arunachalam Thomas Burke Caroline McKay Xiting Cao Rachael Sorg David P Carbone |
| author_facet | Amy P Abernethy Ashwini Arunachalam Thomas Burke Caroline McKay Xiting Cao Rachael Sorg David P Carbone |
| author_sort | Amy P Abernethy |
| collection | DOAJ |
| description | <h4>Purpose</h4>To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations.<h4>Methods</h4>Using a nationally representative electronic health record data from the Flatiron dataset which included 162 practices from different regions in US, we identified patients (≥18 years old) newly diagnosed with stage IV NSCLC initiating first-line anticancer therapy (November 2012- January 2015, with follow-up through July 2015). Patients with documented epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) translocation were excluded. Anti-cancer drug therapy and overall survival were described overall, and by histology.<h4>Results</h4>A total of 2,014 patients with stage IV NSCLC without known EGFR or ALK genomic tumor aberrations initiated systemic anticancer therapy, 22% with squamous and 78% with nonsquamous histology. Their mean (SD) age was 67 (10) years, 55% were male, and 87% had a smoking history. In nonsquamous NSCLC, carboplatin plus pemetrexed either without (25.7%) or with bevacizumab (16%) were the most common regimens; 26.6% of nonsquamous patients receiving induction therapy also received continuation maintenance therapy. In squamous NSCLC, carboplatin plus paclitaxel (37.6%) or nab-paclitaxel (21.1%) were the most commonly used regimens. Overall median OS was 9.7 months (95% CI: 9.1, 10.3), 8.5 months (95% CI: 7.4, 10.0) for squamous, and 10.0 months (95% CI: 9.4, 10.8) for nonsquamous NSCLC.<h4>Conclusion</h4>The results provide context for evaluating the effect of shifting treatment patterns of NSCLC treatments on patient outcomes, and for community oncology benchmarking initiatives. |
| format | Article |
| id | doaj-art-40f05bf53e634a3cbdb1167ee3670a0a |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-40f05bf53e634a3cbdb1167ee3670a0a2025-08-20T03:04:34ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017842010.1371/journal.pone.0178420Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.Amy P AbernethyAshwini ArunachalamThomas BurkeCaroline McKayXiting CaoRachael SorgDavid P Carbone<h4>Purpose</h4>To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations.<h4>Methods</h4>Using a nationally representative electronic health record data from the Flatiron dataset which included 162 practices from different regions in US, we identified patients (≥18 years old) newly diagnosed with stage IV NSCLC initiating first-line anticancer therapy (November 2012- January 2015, with follow-up through July 2015). Patients with documented epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) translocation were excluded. Anti-cancer drug therapy and overall survival were described overall, and by histology.<h4>Results</h4>A total of 2,014 patients with stage IV NSCLC without known EGFR or ALK genomic tumor aberrations initiated systemic anticancer therapy, 22% with squamous and 78% with nonsquamous histology. Their mean (SD) age was 67 (10) years, 55% were male, and 87% had a smoking history. In nonsquamous NSCLC, carboplatin plus pemetrexed either without (25.7%) or with bevacizumab (16%) were the most common regimens; 26.6% of nonsquamous patients receiving induction therapy also received continuation maintenance therapy. In squamous NSCLC, carboplatin plus paclitaxel (37.6%) or nab-paclitaxel (21.1%) were the most commonly used regimens. Overall median OS was 9.7 months (95% CI: 9.1, 10.3), 8.5 months (95% CI: 7.4, 10.0) for squamous, and 10.0 months (95% CI: 9.4, 10.8) for nonsquamous NSCLC.<h4>Conclusion</h4>The results provide context for evaluating the effect of shifting treatment patterns of NSCLC treatments on patient outcomes, and for community oncology benchmarking initiatives.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable |
| spellingShingle | Amy P Abernethy Ashwini Arunachalam Thomas Burke Caroline McKay Xiting Cao Rachael Sorg David P Carbone Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. PLoS ONE |
| title | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. |
| title_full | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. |
| title_fullStr | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. |
| title_full_unstemmed | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. |
| title_short | Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. |
| title_sort | real world first line treatment and overall survival in non small cell lung cancer without known egfr mutations or alk rearrangements in us community oncology setting |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0178420&type=printable |
| work_keys_str_mv | AT amypabernethy realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT ashwiniarunachalam realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT thomasburke realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT carolinemckay realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT xitingcao realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT rachaelsorg realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting AT davidpcarbone realworldfirstlinetreatmentandoverallsurvivalinnonsmallcelllungcancerwithoutknownegfrmutationsoralkrearrangementsinuscommunityoncologysetting |